“Sure. Like I said in my opening comments, we completed the trial. There's a six month follow-up, Larry. That means that, we will be on target here to file for CE mark by the end of this year.”

In context

“out the facts, the science and the data and we stand behind our products. Robbie Marcus: Appreciate it, Robert. Thanks a lot. Operator: Our next question will come from Larry Biegelsen from Wells Fargo. Larry Biegelsen: Good morning. I'll echo, Robbie's, congratulations on the strong start to the year here. Robert, I just wanted to focus on EP. A multipart question here, but just one. The EP business grew nicely in the first quarter in the U.S. and outside the U.S. Can you talk about what drove that? What you're seeing with PFA in the different geographies? Your expectations for your EP business going forward before the Volt launch? Just lastly, it sounds like we should expect the Volt approval in Europe sometime next year based on the filing date. Just want to confirm that. Robert Ford: Sure. Like I said in my opening comments, we completed the trial. There's a six month follow-up, Larry. That means that, we will be on target here to file for CE mark by the end of this year. Then, it's just going to depend on that process. I think that's probably our anchor point here is getting the filing in before the end of the year. Yes, I mean, I'm not surprised by our EP growth. I know many on the call might be, but I'm not surprised. First of all, it's an important therapy. It's an underpenetrated disease. We know there's plenty of growth in this segment, and as a result of that, it's highly competitive. But we haven't been surprised by the growth. If you look at PFA, it's been in Europe for three years. If you average our growth rate over those last three years in Europe, we've been growing mid-teens, and the growth, it remains broad base. It was broad based in Europe, again, this quarter where we saw double-digit growth in ablation catheters. Not just on the mapping”